No Data
Sino Medical Sciences Technology Inc.'s (SHSE:688108) 8.9% Gain Last Week Benefited Both Individual Investors Who Own 53% as Well as Insiders
Sino Medical Sciences Technology Inc. (688108.SH): The company's coronary products have received registration certificates overseas.
Glory Exchange, March 5th丨Sino Medical Sciences Technology Inc. (688108.SH) announced that the company submitted the registration application materials for the HT Supreme drug-eluting Brackets system to the Ministry of Health (MoH) of Vietnam in April 2023. Recently, the company received a notification from MoH that the submitted registration application materials have been approved by MoH. Scope of application: The HT SupremeTM drug-coated coronary Brackets system is suitable for improving symptoms caused by primary coronary artery lesions (length ≤ 40 millimeters).
Sano Healthcare: 2025-005: Sano Healthcare Science & Technology Co., Ltd. 2024 Annual Performance Report Announcement
2025-005: Sano Medical Science & Technology Co., Ltd. 2024 Annual Performance Report Announcement
Sales of two centralized procurement products have increased significantly. Sino Medical Sciences Technology Inc. is expected to turn a profit in 2024, and the Brackets are anticipated to obtain registration certification within the year.
① The company's new spiny balloon product also started large-scale sales in 2024, but the admission rate for the spiny balloon is lower than expected; ② The subsidiary Sinopharm ShenChang officially began production in the second quarter of 2023. Due to the short period of production, the capacity utilization rate is relatively low, resulting in higher fixed costs allocated per unit product.
Sino Medical Sciences Technology Inc. (688108.SH): Net income of 1.5211 million yuan in 2024, turning a loss into profit year-on-year.
Gelonghui, February 26丨Sino Medical Sciences Technology Inc. (688108.SH) announced the performance report for 2024. During the reporting period, the company achieved total revenue of 458.7393 million yuan, an increase of 33.64% compared to the same period last year; achieved a net income attributable to the parent company's shareholders of 1.5211 million yuan, an increase of 103.84% compared to the same period last year; achieved a net income attributable to the parent company's shareholders, excluding non-recurring gains and losses of -17.5065 million yuan, an increase of 64.79% compared to the same period last year. During this reporting period, the company's losses were significantly reduced compared to the same period last year, primarily due to the substantial year-on-year growth in revenue.
There's Reason For Concern Over Sino Medical Sciences Technology Inc.'s (SHSE:688108) Massive 41% Price Jump
